2019: year of the life sciences mega-deal
This contributed article about M&A in life sciences in 2019 covers deal structures, shareholder activism, CFIUS and antitrust enforcement. By US partners at Cooley
Contributed column
Brexit: impact on cross border M&A: it’s not all bad
Alan Farkas, partner at Dorsey & Whitney, has been advising companies on Brexit, and despite some bleak reports he believes there are some positive developments.
Will tokenisation disrupt venture capital and private equity
Investing in funds has been the preserve of pension funds, funds of funds, HNWs & large corporates. But distributed ledger technology, which underpins cryptocurrencies, has the potential to widen access to these asset classes (regulation permitting) & increase liquidity in an otherwise illiquid asset. Ashfords’ Giles Hawkins and Cynthia Ma write
